Fusion Pharmaceuticals, a cancer radiotherapy startup, recently completed a $25 million Series A round of financing, Johnson & Johnson's innovative lead. These funds will be used to support Fusion antibody-targeted radiotherapy Phase Ia trials. In addition, the Canadian biotech company plans to conduct a proof-of-concept trial of non-small cell lung cancer (NSCLC).
This treatment concept is derived from the Centre for Probe Development and Commercialization (CPDC) in Canada. The organization works with the imaging probe industry and research organizations. The idea of ​​CPDC is to combine the ability of alpha particle radiation therapy to fight cancer with the payload molecule, and its main candidate, FPX-01, uses this concept.
Dr. John Valliant, founder and CEO of Fusion, said in a statement, "The alpha particles released by medical isotopes can be used to kill tumor cells with high precision and ability, and can complement the activation of the immune system. The focus of Fusion is to combine our expertise in drug development and production with the corresponding targeting molecules to create a new generation of treatments that better address cancer treatment issues."
Vaillant founded CPDC in 2008. Since seeing this method has great potential, it has also established Fusion. He has convinced some well-known companies to participate.
European venture capital company HealthCap also participated in the Fusion A round of financing. The venture capital firm previously funded Algeta in Bayer's $2.9 billion acquisition of the cancer radiotherapy company Algeta, and later helped its founders create the Nordic Nanovector in 2009. Nanovector's flagship candidate is a drug that combines antibodies with radionuclides. During the acquisition of Bayer, Algeta is developing the use of monoclonal antibodies to load alpha particles to release radionuclides é’227.
TPG Biotech, Genesys Capital and FACIT also voted for Fusion's Series A financing.
Our company specializes in providing Nootropics raw materials -Nootropics Nootropics Nootropics powder Nootropic Active Pharmaceutical Ingredients Nootropics peptides
We also provide Active Pharmaceutical Ingredients // Bodybuilding Peptide //Sarms and so on
Nootropics , Nootropics powder , Nootropic Active Pharmaceutical Ingredients , Nootropics peptides
XI AN RHINE BIOLOGICAL TECHNOLOGY CO.,LTD , https://www.rhinebioteches.com